

Macrophage migration inhibitory factor of the parasitic nematode *Trichinella spiralis*

Timothy H. P. TAN*, Steve A. V. EDGERTON*, Rashmi KUMARI*, Mark S. B. McALISTER†, S. Mark ROWE‡, Sylvia NAGL§, Laurence H. PEARL‡, Murray E. SELKIRK||, Albert E. BIANCO¶, Nicholas F. TOTTY**, Chris ENGWERDA*, Carolyn A. GRAY*¹ and David J. MEYER*²

*Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, U.K., †Department of Crystallography, Birkbeck College, Malet St., London WC1E 7HX, U.K., ‡The Institute for Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London SW6 6JB, U.K., §Department of Biochemistry and Molecular Biology, University College London, Darwin Building, Gower St., London WC1E 6BT, U.K., ||Department of Biochemistry, Imperial College of Science Technology and Medicine, London SW7 2AY, U.K., ¶Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., and **Protein Analysis Laboratory, Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London WC2A 3PX, U.K.

cDNAs were obtained for macrophage migration-inhibitory factor (MIF)/L-dopachrome methyl ester tautomerase homologues from the parasitic nematodes *Trichinella spiralis* (TsMIF) and *Trichuris trichiura* (TtMIF). The translated sequences, which were partly confirmed by sequencing of proteolytic fragments, show 42 and 44% identity respectively with human or mouse MIF, and are shorter by one C-terminal residue. Unlike vertebrate MIF and MIF homologues of filarial nematodes, neither TsMIF nor TtMIF contain cysteine residues. Soluble recombinant TsMIF, expressed in *Escherichia coli* showed secondary structure (by CD spectroscopy) and quaternary structure (by light-scattering and gel filtration) similar to that of the trimeric mammalian MIFs and D-dopachrome tautomerase. The catalytic specificity of recombinant TsMIF in the ketonization of phenylpyruvate ($1.4 \times 10^6 \text{ M}^{-1} \cdot \text{s}^{-1}$) was comparable with that of human MIF, while that of *p*-hydroxyphenylpyruvate ($9.1 \times 10^4 \text{ M}^{-1} \cdot \text{s}^{-1}$) was 71-fold lower. TsMIF showed high specificity in tautomerization of the methyl ester of L-dopachrome compared

with non-esterified L-dopachrome (> 87000-fold) and a high k_{cat} ($\approx 4 \times 10^4 \text{ s}^{-1}$). The crystal structure, determined to 1.65 Å (1 Å = 0.1 nm), was generally similar to that of human MIF, but differed in the boundaries of the putative active-site pocket, which can explain the low activity towards *p*-hydroxyphenylpyruvate. The central pore was blocked, but was continuous, with the three putative tautomerase sites. Recombinant TsMIF (5 ng/ml–5 pg/ml) inhibited migration of human peripheral-blood mononuclear cells in a manner similar to that shown by human MIF, but had no effect from 5 to 500 ng/ml on anti-CD3-stimulated murine T-cell proliferation. TsMIF was detected in supernatants of *T. spiralis* larvae cultured *in vitro* at 6 ng/ml (55 ng/mg total secreted protein). In conclusion TsMIF has structural, catalytic and cell-migration-inhibitory properties which indicate that it is partially orthologous to mammalian MIF.

Key words: cytokine, dopachrome, tautomerase, *Trichuris*.

INTRODUCTION

Parasitic helminths are remarkable for their ability to survive for long periods in constant interface with the protective immune systems of their host. Numerous immune-protective and immune-evasive mechanisms have been described, including surface shedding, resurfacing with host molecules, rapid tissue relocation, antioxidant defence systems and the production of immunomodulatory factors [1,2]. The nematode *Trichinella spiralis* is able to parasitize a wider range of mammalian species than any other helminth. The larva invades a muscle cell transforming it into a nurse cell, which is a stable intracellular niche unique among helminths. The nurse cell secretes a collagen capsule and stimulates angiogenesis. Infection with *T. spiralis* results in depression of various parameters of immunity, including delayed type hypersensitivity and responses to bacterial lipopolysaccharide [3,4]. However, little is known about the immunological interactions which support this host–parasite relationship.

A homologue of macrophage migration-inhibitory factor (MIF) was the first molecule isolated from *T. spiralis* showing similarity to a mammalian cytokine and which might contribute to subversion of host defences [5].

Mammalian MIF has shown a bewildering array of cellular effects. It is inhibitory not only towards monocyte–macrophage migration, but also glucocorticoid activity [6], immunoglobulin synthesis [7], natural killer-cell activity [8] and p53-dependent apoptosis [9]. MIF also shows positive effects on T-lymphocyte activation [10], insulin release [11], angiogenesis [12], fibroblast growth [13], sepsis [14] and macrophage nitric oxide synthesis [15]. Recently, the identification of an intracellular interaction of MIF with Jab1, a co-activator of activator protein-1 ('AP-1') transcription which increases the expression of pro-inflammatory genes, and promotes degradation of the cyclin-dependent kinase inhibitor p27^{kip1}, indicates how MIF may be involved in the control of the cell cycle [16]. MIF is genetically [17,18] and structurally [19] related to 'D-dopachrome tautomerase' with

Abbreviations used: AMSH, a signal-transducing adaptor protein involved in interleukin-2- and granulocyte–macrophage-colony-stimulating-factor-stimulated cell growth; MIF, macrophage migration-inhibitory factor; (r)TsMIF, (recombinant) *Trichinella spiralis* MIF; TtMIF, *Trichuris trichiura* MIF; HsMIF, *Homo sapiens* (human) MIF; PDB, Protein Databank (Brookhaven, CT, U.S.A.); CC, correlation coefficient; IL, interleukin; IFN- γ , interferon- γ ; CNS, Crystallography and NMR System; NCS, non-crystallographic symmetry.

¹ Present address: Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K.

² To whom correspondence should be addressed (e-mail david.meyer@lshtm.ac.uk).

The nucleotide sequence data discussed are available from the DDBJ, EMBL, GenBank® and GSDB Nucleotide Sequence Databases under the accession numbers AJ012740 (*Trichinella spiralis* MIF), AJ237770 (*Trichuris trichiura* MIF) and AJ237610 (for partial *T. trichiura* AMSh); the crystal structure co-ordinates of *T. spiralis* MIF are in the PDB (file 1HFO).

which MIF shares the spurious enzyme activity. The crystal structure of rat, human and mouse MIF is a unique trimeric barrel forming a narrow pore [20,21]. The monomer has a secondary structure similar to that of the dimer of interleukin-8 (IL-8) [21]. The tautomerase activity is associated with the N-terminal proline residue, which has a relatively low pK_a [22–24]. MIF homologues have also recently been found in several filarial nematodes: *Brugia pahangi*, *B. malayi*, *Wuchereria bancrofti* and *Onchocerca volvulus* and the intestinal nematode *Trichuris muris* [5,25]. Immunocross-reactive material was also detected in *Ascaris lumbricoides* (human roundworm) and *Diriofilaria immitis* (dog heartworm) [25] and a novel MIF homologue from the human whipworm, *Trichuris trichiura* is presented herein.

To facilitate study of the possible role(s) of *T. spiralis* MIF (TsMIF) in parasite-directed subversion of host immunoregulation, it has been cloned, expressed in *Escherichia coli* and characterized with respect to structural, enzymic and cytokine properties.

EXPERIMENTAL

Organisms

T. spiralis larvae were obtained by pepsin digestion of infected mouse muscle [26] and snap-frozen. *T. trichiura* adults for *Trichuris trichiura* MIF (TtMIF) isolation were provided by Dr M. Albonico (Public Health Laboratory, Ivo de Carneri, Zanzibar, Tanzania) and Dr Q. D. Bickle (London School of Hygiene and Tropical Medicine, London, U.K.). They were collected from 48 h stool samples of mebendazole-treated children in PEMBER, Zanzibar, and frozen. *T. trichiura* adults for RNA isolation were obtained during investigative colonoscopy for chronic inflammatory bowel syndrome (Mona Campus, University of the West Indies, Jamaica) and snap-frozen.

Isolation and characterization of TtMIF

T. trichiura adults (1.2 g) were powdered in a pestle and mortar under liquid nitrogen and the L-dopachrome methyl ester tautomerase activity (putative TtMIF, see below for assay) purified from the soluble extract using a 1 ml column of phenyl-agarose as described for the isolation of MIF homologues from *T. muris* and *B. pahangi* [5]. Purity was assessed by reverse-phase HPLC [5] and SDS/PAGE. Automated Edman sequencing was performed on 20 pmol of intact TtMIF using fast-cycle chemistry on an Applied Biosystems Procise HT sequencer [27]. A 50 pmol portion of TtMIF was digested overnight with immobilized trypsin in 25 mM ammonium bicarbonate at 37 °C. Peptides were separated by reverse-phase HPLC using a 0.8 mm × 150 mm column and sequenced as above.

Primary structure of native TsMIF

Native TsMIF, isolated from the soluble extract of *T. spiralis* larvae by phenyl-agarose chromatography and cation-exchange FPLC [5] was digested in 0.1 M sodium bicarbonate with endoprotease Glu-C (Boehringer) followed by trypsin, and fragments purified by reverse-phase HPLC were sequenced using an Applied Biosystems 470A sequencer.

cDNA isolation

The cDNAs coding for both TsMIF and TtMIF were isolated using 3'-rapid amplification of cDNA ends. The primers TsM-F (5'-GCGGCTGCGAATTCATGCCWATYTTYACIYTBA-

YAC-3') and TtM-F (5'-GCGGCTGCGAATTCATGCCWATYTTYACRTTYWSIAC-3') were designed from the N-terminal amino acid sequences of TsMIF [5] and TtMIF (P81529 and P81748 respectively). The nucleotide sequence degeneracy was restricted according to the codon usage of *Caenorhabditis elegans* as used for selecting another *T. spiralis* cDNA [28].

TsMIF cDNA was isolated from *T. spiralis* muscle-stage larvae powdered under liquid nitrogen. Total RNA was obtained using the RNeasy Midi Kit (Qiagen), and first-strand cDNA synthesized using the SuperScript Preamplification System (Life Technologies) with primer MRSdT. The initial PCR reaction mixture consisted of PCR buffer mix containing 3.0 mM Mg^{2+} , 4% (v/v) DMSO, 2 μ l of *T. spiralis* cDNA and 1 pmol of primer TsM-F. During the first cycle, amplification was carried out at 94 °C for 180 s, 48 °C for 60 s and 72 °C for 300 s. Immediately after the denaturing step of the second cycle, 0.2 pmol of primers MRS (5'-GGGGAATTCGATATCGGTACCT-3') and 5TM (5'-GCGGCTGCGAATTCATG-3') were added to the original PCR reaction mixture. For cycles 2–45, amplification was carried out at 94 °C for 30 s, 54 °C for 30 s and 72 °C for 90 s. The DNA polymerase used was TaqPlus Precision (Stratagene) or Vent_R (New England Biolabs) for blunt-end cloning.

T. trichiura RNA was obtained by powdering worms under liquid nitrogen and extracting with guanidinium thiocyanate. Polyadenylated RNA was separated using an oligo-dT spun column and double-stranded cDNA synthesized using Moloney-leukaemia-virus reverse transcriptase and the klenow fragment of DNA polymerase I. Two sets of PCR were used to isolate the TtMIF cDNA. In the first PCR, the reaction mixture contained PCR buffer mix plus 1.5 mM Mg^{2+} , 4% DMSO, 2 μ l of *T. trichiura* cDNA, 1 pmol of primer MRSdT (5'-GGGGAATTCGATATCGGTACCT₁₆-3') and Vent_R DNA polymerase. This PCR was carried out at 94 °C for 30 s, 42 °C for 30 s, and 72 °C for 60 s for 35 cycles. Approx. 5% of this PCR mixture was used as the template for the second PCR, which was carried out as described above for TsMIF using primer TtM-F.

The PCR products from both *T. spiralis* cDNA and *T. trichiura* cDNA were cloned directly into pGEM-T Easy Vector (Promega) and recombinant plasmids were sequenced using the Thermo Sequenase dye terminator cycle sequencing kit (Amersham Life Sciences) and M13 primers.

Expression of rTsMIF (recombinant TsMIF)

The TsMIF PCR product was restricted with *Eco*RI, cloned into *Eco*RI-restricted pKK223-3 expression vector (Pharmacia Biotech) and transformed into *E. coli* JM109 competent cells (Promega). Colonies with recombinant plasmids were then cultured in liquid and induced with 1 mM isopropyl thio- β -D-galactopyranoside. After 3 h culture, cells were pelleted, sonicated in homogenization buffer [150 mM NaCl/1 mM EDTA/50 μ M PMSF/1 μ M leupeptin/20 mM sodium phosphate (pH 7.0)] and the soluble extract obtained by ultracentrifugation. The extracts were tested for rTsMIF expression by SDS/PAGE and L-dopachrome methyl ester tautomerase activity (see below).

rTsMIF was purified from a positively expressing clone as follows. The soluble extract, obtained as above, from a 500 ml exponential-phase bacterial culture was applied to a 3 ml column of phenyl-agarose in homogenization buffer at 4 °C. The column was washed thoroughly with this buffer (minus protease inhibitors), and the rTsMIF subsequently eluted with EGEP buffer [40% (v/v) ethylene glycol/1 mM EDTA/20 mM sodium phosphate (pH 7.0)], the eluate being monitored for L-dopachrome methyl ester tautomerase activity. A stock of 0.5 mg/ml TsMIF was kept in this solution at 4 °C. Portions

were dialysed against PBS and re-applied to phenyl-agarose in this buffer and eluted with 20 mM Hepes, pH 7.2. After sterile filtration such solutions of TsMIF of approx. 50 µg/ml were stored at 4 °C and diluted into tissue-culture medium for cellular studies. A larger amount of rTsMIF for structural analysis was prepared from 5 litres of induced culture. Cells were disrupted with a French press and the soluble supernatant after ultracentrifugation was applied to a column of phenyl-agarose and thoroughly washed as described above. TsMIF was then eluted with a linear gradient from 150 mM NaCl/1 mM EDTA/20 mM sodium phosphate, pH 7.0, into 20 mM mM Hepes, pH 7.0, over 5 column volumes and then concentrated by ultrafiltration and further purified on a Superdex 75 column (100 cm × 2.5 cm) in 20 mM Hepes, pH 7.0. The concentration of purified TsMIF samples were estimated from A_{280} ($\epsilon_{280} = 8250 \text{ M}^{-1} \cdot \text{cm}^{-1}$), and purity was determined by reverse-phase HPLC and SDS/PAGE.

Freeze-dried purified recombinant human MIF (rHsMIF) was obtained from Dr Andrej Francky (BioHit d.o.o., Ljubljana, Slovenia) and solutions prepared in EGEP buffer and sterile Hepes equivalent to those for rTsMIF (see above). The thiol content of rHsMIF was 2.2 ± 0.1 mol/monomer, determined by titration with 2,2'-dithiobis(nitrobenzoic acid) in guanidinium chloride [29].

Structural studies of TsMIF in solution

MS

Mass spectra were collected on a VG Platform electrospray mass spectrometer (Micromass). Samples were desalted by dialysis against deionized water for 24 h. Samples were then injected (10 µl) under standard conditions (80–200 pmol/µl in 50% acetonitrile/0.25% formic acid). Delivery solvent (50% acetonitrile) was pumped at a flow rate of 10 µl/min. Twelve 10 s scans were accumulated for each sample over the m/z range 750–1150. The source temperature was set at 45 °C and the cone voltage was 41 V. Spectra were processed using the Masslynx software supplied with the instrument (version 3.0 b5). Horse heart myoglobin (molecular mass 16951.5 Da) was used to calibrate the instrument [30].

CD spectroscopy

CD spectra were recorded using a nitrogen-flushed Aviv 202SF spectropolarimeter with samples in 0.01–1.0-cm-path-length quartz cells at room temperature. The protein concentrations of samples ranged from 0.2 to 10 mg/ml, in 20 mM Hepes buffer, pH 8.0. Wavelength scans were recorded five times using a 0.2 nm step size and a 2 s averaging time. The averaged spectra were imported into a spreadsheet program (Origin) and corrected for baseline drift and then smoothed. Estimates of secondary-structural content were determined by quantitative analysis of the spectra using linear least squares [31] and singular value decomposition [32]. A value of < 0.1 for the normalized root-mean-square deviation for each curve is indicative of a good fit [33].

Gel filtration

Size-exclusion chromatography was performed using a HiPrep Sephacryl S-100 column (16 mm × 60 mm; Pharmacia) controlled by an Acta FLPC system. The column was run in 20 mM NaCl/20 mM Hepes, pH 8.0, at 0.5 ml/min, using 1 ml sample volumes containing 0.1–1 mg of protein.

Light-scattering

Dynamic light-scattering measurements were obtained using a DynaPro-801 instrument equipped with a 100 µl cell (Protein Solutions, Charlottesville, VA, U.S.A.). Samples of TsMIF, at concentrations of 2, 5 and 10 mg/ml in 20 mM Hepes/20 mM NaCl, pH 8.0, were passed through 0.2 µm-pore-size membrane filters (Whatman) during injection. Measurements were taken at room temperature (21.2 ± 0.16 °C), and data was analysed using Autopro software, which calculated the translational diffusion coefficient, D_T , and thence the apparent Stokes radii. The instrument was calibrated with a set of 23 standard proteins ranging in size from 8 to 1250 kDa, allowing reliable estimation of molecular mass from measurements of diffusion coefficients. The photon count rate varied by less than 3% in all experiments. Sum of squares errors for all readings were less than 0.5, indicating that the data was of high quality with a high signal-to-noise ratio.

Tautomerase activities

For tautomerase assays, MIF stocks (0.5 mg/ml) in EGEP buffer were diluted 20–100-fold in the same buffer and kept on ice. Dopachrome tautomerase activity was measured spectrophotometrically at 32 °C in 10 mM sodium phosphate/0.5 mM EDTA, pH 6.4, using 0.4 mM L-3,4-dihydroxyphenylalanine or its methyl ester or the D-enantiomer plus limiting sodium *m*-periodate to generate the dopachromes immediately prior to addition of MIF [34]. An ϵ_{474} of $3700 \text{ M}^{-1} \cdot \text{cm}^{-1}$ was used for each dopachrome. Specific activities were obtained from the mean values from triplicate assays differing by less than 12%.

Approximate kinetic data for the relatively rapid tautomerization of L-dopachrome methyl ester were obtained from desaturation curves as follows: to 0.55 mM L-dopachrome methyl ester was added sufficient recombinant MIF to catalyse about 70% tautomerization in 3 min and the end point obtained by addition of an excess of enzyme. Tangential rates were determined from the curve at 10–12 substrate concentrations. The non-catalytic rate at these substrate concentrations was subtracted by reference to tangential rates from a similar assay lacking enzyme. Since the K_m values were approx. 10-fold higher than the maximum substrate concentration range studied, approximate kinetic data only were obtained from double-reciprocal plots.

The tautomerization (ketonization) of phenylpyruvate and *p*-hydroxyphenylpyruvate was assayed at 288 and 300 nm respectively at 23 °C [35]. Specific activities were obtained using 0.1 mM substrate, and kinetic data were obtained from desaturation curves as described above. The data were fitted to a rectangular hyperbola using the Kinenort software (Dr A. G. Clark, University of Wellington, Wellington, New Zealand) to obtain kinetic constants.

Crystal structure of TsMIF

Crystallization and data collection

TsMIF protein at 33 mg/ml was screened for crystallization using the commercial Hampton Crystallization Screens I and II [36]. The trials were carried out under oil using the microbatch method. Crystals were observed under 12 of the 98 conditions. Four conditions showing the best initial crystals were optimized in hanging drops to give diffraction-quality crystals. The highest diffracting crystals were grown with final conditions in the crystallization drop of 16.5 mg/ml TsMIF, 400–600 mM ammonium acetate, 30–36% 4000- M_r poly(ethylene glycol) ('PEG4K') and 100 mM sodium acetate at pH 4.6. After initial

Table 1 Diffraction and refinement data

Parameter	Value
Total number of reflections	163 895
Unique reflections	67 115
Average multiplicity	2.3
Average $\ \sigma I^*$	3.6
Average completeness	97.6
Average R_{merge}^\dagger	0.057
Reflections in highest shell	16 174
Unique in highest shell	7060
Multiplicity in highest shell	2.2
$\ \sigma I^*$ in highest shell	2.5
Completeness in highest shell	97.6
R_{merge}^\dagger in highest shell	28.1
Number of crystals	1
Number of protein atoms	5134
Number of water molecules	1032

* $\| \sigma I^*$ is average intensity in resolution bin/average S.D.

† $R_{\text{merge}} = (\sum_{hkl} |I_{hkl} - \langle I_{hkl} \rangle|) / (\sum_{hkl} I_{hkl})$, where I_{hkl} is the intensity for each observation/symmetry equivalent of a particular reflection, hkl , and $\langle I_{hkl} \rangle$ the average intensity over all observations/symmetry equivalents of the reflection (0.057 refers to the overall R_{merge} of the data and 28.1% (or 0.281) the R_{merge} in the highest resolution bin).

in-house data collection on a RU300HB Rigaku generator to determine the cell, space-group and diffraction characteristics, a full data set was collected to 1.5 Å (1 Å = 0.1 nm) on beamline ID14-3 ($\lambda = 0.931$ Å) at the ESRF (European Synchrotron Radiation Facility, Grenoble, France), using high- and low-resolution sweeps. The cell was refined to $a = 110.10$ Å, $b = 88.38$ Å, $c = 86.36$ Å, $\beta = 131.1^\circ$, space group C2. Calculation of the Matthews coefficient [37] indicated that the cell contained four molecules (equivalent to two molecules in the asymmetric unit), resulting in a solvent content of 43%. The data was processed using MOSFLM and sorted, merged, scaled and truncated using programs from the CCP4 [38] suite of programs (Table 1).

Structure determination and refinement

The structure was solved by molecular replacement with the human MIF structure [PDB (Protein Database, Brookhaven, CT, U.S.A.) entry 1MIF] [20] using AMoRe contained in the CCP4 [38] suite of programs. Cross-rotation and translation-function searches were carried out using data to 2.0 Å. The cross rotation yielded two unambiguous solutions [correlation coefficient (CC) = 22.2 and CC = 19.6, next highest solution CC = 10.5]. The two solutions were refined as rigid bodies using data to 1.65 Å, giving a final CC of 65.5.

Refinement was carried out using the slowcool-torsional-refinement strategy in CNS (Crystallography and NMR System) version 1.0 [39]. Initially, sixfold non-crystallographic symmetry (NCS) was used in refinement. The NCS was relaxed to twofold and later removed in final cycles of refinement and model building. The model was manually rebuilt with the program O [40]. The model was stereochemically checked using PROCHECK [38]. Water molecules were located using the water-picking routine of CNS and checked manually in O before being included in refinement. The final $R = 0.225$ and $R_{\text{free}} = 0.281$, with 1033 water molecules modelled. The structure has been deposited at the PDB as file 1HFO. R (the crystallographic R -factor) is defined as follows:

$$R = (\sum_{hkl} |F_{\text{obs}} - F_{\text{calc}}|) / (\sum_{hkl} |F_{\text{obs}}|)$$

where F_{obs} are the observed structure factor amplitudes and F_{calc}

those determined from the model. R_{free} is R but for 5% of the total number of reflections that have been excluded from the refinement process.

Cellular studies

Migration of human monocytes was studied using Transwell chemotaxis chambers (6.5-mm-diameter polycarbonate filters with 5 µm pores; Costar) using methods based on those in [25]. Monocytes were prepared from buffy coat of healthy volunteers (North Thames Blood Transfusion Service, Colindale, London, U.K.) after dilution with 5 vol. of medium A [RPMI 1640 medium (Gibco BRL) containing 25 mM Hepes, 2 mM L-glutamine, 1 mM sodium pyruvate and 100 unit/ml penicillin/100 µg/ml streptomycin], by centrifugation on Ficoll gradient using Histopaque 1077 (Sigma). The monocyte fraction was washed and erythrocytes lysed with Tris/NH₄Cl buffer (0.14 M NH₄Cl/17 mM Tris/HCl, pH 7.2). Cells were resuspended, counted and diluted to 2×10^6 cells/ml together with purified MIF (5 ng–5 µg/ml diluted from a 50 µg/ml stock in 20 mM Hepes, pH 7.2) or, as a control, an equal volume of Hepes buffer lacking MIF. For migration-inhibition assay, the upper filter chambers were separated and 600 µl of medium A was placed in the lower chambers. A 100 µl portion of monocyte suspension (control or with added MIF) was then added to the upper chambers, each being immediately placed on to a lower chamber. Quadruplicate samples were prepared. After incubation at 37 °C/5% CO₂ for 3 h, the non-migrated cells on the upper surface of the filters were gently scraped off and the remainder removed by aspiration. The migrated cells on the lower surface were fixed with methanol and stained using a Diff Quick kit (Dade-Behring A. G., Duedingen, Switzerland). The membranes were mounted on glass slides in Deepex (BDH/Merck). The slides were coded and randomized prior to quantitative analysis. Migrated cells were counted in five random fields per filter. After unblinding, the 20 fields per sample were averaged, the S.D. calculated and the samples statistically compared by a two-tailed Student's t test.

T-cell activation was studied using splenocytes isolated from female BALB/c mice and measuring proliferation and cytokine production. CD4⁺ T cells were isolated from splenocytes by positive selection using magnetically activated cell sorting according to the protocol provided by the manufacturer of the selection columns (MS+) and anti-CD4-antibody (L3T4)-conjugated microbeads (Miltenyl Biotec, Bergisch Gladbach, Germany). Cells were cultured in 96-well, flat-bottomed plates [Nunc (now part of Life Technologies, Paisley, Renfrewshire, Scotland, U.K.)] and T cells were stimulated with 10 µg/ml immobilized (plate-bound) anti-CD3 ϵ mAb (145-2C11) in different concentrations of TsMIF solutions, and proliferation was measured after 36 h by incorporation of [³H]thymidine. Prior to the [³H]thymidine pulse (after 24 h of culture), 25 µl of supernatant was removed and frozen for subsequent quantitative cytokine analysis. IL-2 and IL-4 production were measured using proliferation of a natural killer-cell line (10⁴ cells/well), in the presence of neutralizing antibodies to IL-4 (11B11, 1 µg/ml) and IL-2 (S4B6, 2 µg/ml) respectively. After 24 h, 10 µl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide ('MTT'; 5 mg/ml) and 100 µl of 0.04 M HCl in propan-2-ol were added to each well, and plates read in an ELISA reader. The assay detected > 0.25 unit/ml IL-2 and > 1 unit/ml IL-4. Interferon- γ (IFN- γ) was measured by antibody-capture ELISA using anti-IFN- γ (R46A2; 2 µg/ml) to capture, and biotinylated anti-IFN- γ (XMG1; 1 µg/ml) for detection; the sensitivity was > 1 unit/ml. Natural killer cells and antibodies used were

Table 2 Comparison of estimates of secondary structure composition derived from CD spectra with those from crystal structure for TsMIF and HsMIF

MIF	Percentage of structure as:			
	α -Helix	β -Sheet	β -Turn	Unordered
TsMIF*	18–25 (26)	43–58 (30)	6–14 (7)	15–26 (37)
HsMIF†	11–25 (28)	30–50 (28)	15–33 (4)	12–24 (40)

* Secondary-structure estimation from CD spectra was performed using the linear least squares [31] and singular-value decomposition [32] methods with reference data sets [33,44]; good-quality curve fits (normalized root-mean-square deviation < 0.1) were obtained for secondary structure analysis using both methods; the secondary structure of crystalline TsMIF is given in parentheses.

† The range of secondary-structure composition of HsMIF using several different CD-based prediction methods estimates [43], and in parentheses the data from the crystal structure [20] (PDB code 1MIF).

cultures carrying recombinant plasmids obtained. Addition of inducer to liquid cultures resulted in expression of soluble L-dopachrome methyl ester tautomerase activity and a detectable extra band of molecular mass 13 kDa upon SDS/PAGE of the bacterial extract. The rTsMIF was purified from a 500 ml culture for further study of enzymic and cytokine properties. A 3 mg portion of rTsMIF was obtained with minimal losses. The recombinant enzyme showed a specific tautomerase activity similar to that of the enzyme purified from *T. spiralis* (3500 μ mol/min per mg). Of three proteins detectable contaminating rTsMIF in the initial EGEP buffer eluate of the phenyl-agarose column, one, of molecular mass 58 kDa, appeared from SDS/PAGE analysis to be co-induced with TsMIF. It was purified by reverse-phase HPLC, and the first eight residues obtained by Edman degradation, which identified it as tryptophan indole lyase (β -cysteine conjugate lyase). The molecular mass of rTsMIF, determined by electrospray-ionization MS matched the calculated mass of rTsMIF minus the N-terminal methionine residue within 1 mass unit, indicating that there were no further post-translational modifications to rTsMIF. Only one major peak was observed. A larger batch of rTsMIF (30 mg) was prepared for structural analysis.

Secondary and quaternary structure of soluble TsMIF

CD spectroscopy of rTsMIF indicated that it had a high secondary-structure content. Computational secondary-structure analysis [31–33] of the CD spectra suggested that structure of rTsMIF in solution comprised 18–25% α -helix, about 43–58% β -strands, 6–14% β -turn and the remainder 15–26% random coil. These secondary-structure estimates were compared with CD-based secondary-structure analysis of HsMIF that used the same data sets [43] and were found to give similar values (Table 2). Essentially no change was observed in the CD spectra of rTsMIF over a 50-fold concentration range (0.2–10 mg/ml).

The oligomeric state of soluble rTsMIF was assessed by size-exclusion chromatography and dynamic light-scattering. By chromatography, the molecular mass was estimated at 25 kDa. The elution volume was independent of protein concentration over the range 0.1–10 mg/ml, suggesting that the rTsMIF oligomer is relatively stable. This apparent mass agrees closely with that of rat MIF estimated by gel filtration (24.3 kDa), which was subsequently found to be a trimer in the crystal structure. Dynamic-light-scattering analyses were performed with rTsMIF samples at both 5 and 10 mg/ml. Ten separate readings were made for both samples at room temperature. Essentially identical diffusion coefficients [(894 \pm 3.18) $\times 10^{-13}$ m²/s] were observed at both protein concentrations. Baseline values of between 1.000 and 1.001 indicated that the distribution was monomodal and could be fully resolved by a single autocorrelation decay function. Low values for polydispersity (0.483 \pm 0.08 nm) were observed, suggesting that rTsMIF was essentially monodispersed over this concentration range. Comparison of the diffusion coefficient of rTsMIF with those of a range of molecular-mass standards gave an estimated molecular mass of \approx 30 kDa, consistent with trimeric self-association of rTsMIF. The estimated molecular radius of rTsMIF (2.4 nm) is similar to that of human MIF (2.6–2.7 nm) previously measured by this technique [45].

Tautomerase activity

The specific tautomerase activity of TsMIF towards L-dopachrome methyl ester was about 6-fold higher than that of mammalian MIFs as also was its specificity, as judged by relative activity towards unesterified D-dopachrome (7000-fold compared with 72.5-fold lower respectively; Table 3). Since the K_m for L-

Table 3 Tautomerase activities of TsMIF compared with those of human MIF

Specific activities were measured as initial rates over 0.4 min using 0.4 mM substrate at 32 °C, pH 6.4, for the dopachromes and with 100 μ M substrate at 23 °C, pH 6.5 for the phenylpyruvates. Kinetic constants were obtained from desaturation curves.

Substrate	Enzyme	K_m (μ M)	Specific activity (μ mol/min per mg)	V_{max} (μ mol/min per mg)	k_{cat} (s ⁻¹)	k_{cat}/K_m (s ⁻¹ · M ⁻¹)
L-Dopachrome methyl ester*	TsMIF	\approx 5000	3500	\approx 40000	\approx 8100	$\approx 1.6 \times 10^6$
	HsMIF	\approx 5000	580	\approx 6500	\approx 1340	$\approx 0.27 \times 10^6$
L-Dopachrome	TsMIF		< 0.04†			
	HsMIF		< 0.2†			
D-Dopachrome	TsMIF		0.5‡			
	HsMIF		8‡			
Phenylpyruvate	TsMIF	144 \pm 24	420	1026 \pm 135	207	1.4 $\times 10^6$
	HsMIF	249 \pm 36	605	2113 \pm 280	434	1.7 $\times 10^6$
p -Hydroxyphenylpyruvate	TsMIF	783 \pm 125	3.9	34.6 \pm 5.0	7.1	0.009 $\times 10^6$
	HsMIF	168 \pm 11.2	196	524 \pm 35.5	108	0.64 $\times 10^6$

* K_m values too high for accurate kinetic analysis.

† Detectability limit.

‡ Activity too low for kinetic analysis.




Figure 2 Secondary structure assignments of crystalline TsMIF

Secondary structure was assigned as described in [46].




Figure 3 Side view of TsMIF showing secondary structure elements and the disordered loop B66–B73

The Figure was prepared using BOBSCRIPT [47].

dopachrome methyl ester was inaccessibly high, only approximate kinetic data could be obtained. The approximate k_{cat} of 8000 s^{-1} and catalytic specificity greater than $10^6\text{ M}^{-1}\cdot\text{s}^{-1}$ are notable. Catalysis of the ketonization of the physiological substrates phenylpyruvate and *p*-hydroxyphenylpyruvate by human MIF also yielded catalytic specificities in the region of $10^6\text{ M}^{-1}\cdot\text{s}^{-1}$ similar to published values [35] (Table 3). TsMIF showed a similar activity towards phenylpyruvate, but had a lower k_{cat} and higher K_m than HsMIF towards *p*-hydroxyphenylpyruvate, resulting in a 71-fold lower catalytic specificity.

Crystal structure

The secondary and tertiary structure of TsMIF [Figures 2 and 3, and PDB file 1HFO] is very similar to HsMIF, as expected from the high CCs seen during the molecular replacement. In both cases the amount of β -sheet was less than, and the amount of 'unordered' structure greater than, that estimated from the CD-spectroscopic analysis (Table 2). TsMIF forms a trimer of approximate dimensions $50\text{ \AA} \times 50\text{ \AA} \times 40\text{ \AA}$. Each monomer consists of a central core of a four-stranded β -sheet flanked by two anti-parallel helices and a further three very short β -strands. The short β -strands extend the core four-stranded β -sheet of a neighbouring monomer on either side, to create a seven-stranded β -sheet, thus linking the trimer together (Figure 3). The protein

shows several areas of secondary structure that have high mobility. The most obvious is the loop between position B66 to B73. This clearly exists in at least two conformations. It is not known if this has any functional relevance. The 10–18 loop in chains B,C,D and F is also highly mobile, though does not show any signs of alternate conformations. This loop lies on the top surface of the protein. The equivalent loop in chains A and F are less mobile due to intermolecular contacts within the crystal.

A channel is formed down the centre of the trimer from the N- and C-terminal end (Figure 4), which is closed at the other end by a ring formed from the side chains of Asn⁴² and the conserved Gln⁴⁵ from each monomer. In contrast the narrowest point of the channel in HsMIF, which has a valine residue at position 42, is 3–4 Å. Interestingly, position 42 is also asparagine in TtMIF and the *Brugia* MIFs (Figure 1). The channel has no large areas of either positive or negative charge, and overall is very slightly negatively charged.

Active site

A comparison of the putative tautomerase active site of TsMIF with that of HsMIF (Figure 5) shows a close overlap of the active-site residue Pro¹ and the residues closely surrounding it: Ser⁶³, Lys³² and the aromatic grouping Tyr³⁶, Phe^{B349}, Tyr^{B95}, Phe¹¹³ and Trp¹⁰⁸. Electron density is seen in the putative active-site pocket of some subunits very close to Pro¹ (PDB file 1HFO), indicative of a bound ligand.

Residue changes between HsMIF and TsMIF in the active-site region have had the effect of shortening the pocket slightly and making it more hydrophobic. Specifically, changing Tyr⁹⁹ in HsMIF to valine in TsMIF allows His⁹⁷ (Asn in HsMIF) to flip back towards the central channel of the trimer. This allows Met⁹² to move into the active-site pocket. The modelled position of the hydroxy group of hydroxyphenylpyruvate, which is hydrogen-bonded to Asn⁹⁷ in HsMIF [35], is now very close to the sulphur atom of Met⁹². In addition, the side chain of Leu¹⁰¹ (methionine in HsMIF) is also sterically crowding the phenol moiety. Further, the change in orientation of His⁹⁷ removes a polar group from the vicinity of the phenylhydroxy group, thus creating a more hydrophobic environment. These structural differences can explain the low activity of TsMIF towards *p*-hydroxyphenylpyruvate compared with phenylpyruvate (Table 3). Note that the important difference at position 99 (tyrosine in HsMIF as against valine in TsMIF) also occurs in TtMIF and the *Brugia* MIFs (Figure 1), whereas the critical Asn⁹⁷ is retained in TtMIF, but is a glutamate residue in the *Brugia* MIFs. The altered disposition of His⁴⁹ in TsMIF compared with Asn⁴⁹ in HsMIF means that the putative active-site pocket of TsMIF extends right through to the central channel (Figures 4 and 5).

The large difference in tautomerase activity seen between L-dopachrome and L-dopachrome methyl ester (Table 3) can be inferred from the comparison with the phenylpyruvate structures [23]. Assuming that the carboxy-group moiety lies in approximately the same place, there is a close interaction between the



Figure 4 Top (left) and side (right) views of the channels in TsMIF superimposed on the secondary structure

p-Hydroxyphenylpyruvate from 1CA7.pdb is overlaid in the active site. The Figure was created with GRASP [48] and BOBSCRIPT [47].




Figure 5 Superimposition of TsMIF and 1CA7.pdb active sites showing the main differences between TsMIF and HsMIF

TsMIF residues and main chain are shown in blue and those most different from those of HsMIF are labelled. The Figure was created using BOBSCRIPT [47].

carboxy hydroxy group and the side chain of Ile⁶⁴. Methylating the hydroxy group would create a hydrophobic/hydrophobic contact and would also have the effect of pushing the carboxy group a little closer to Pro¹, thus increasing the probability of reaction.

Cellular effects

Cell migration

In order to discern whether TsMIF served only tautomerization functions or could also affect human immune cells as does mammalian MIF, the ability of TsMIF to alter the migration of freshly isolated normal human peripheral-blood mononuclear cells was tested using polycarbonate filter chambers. When TsMIF or HsMIF was added to the top chamber (with the

monocytes), inhibition of migration was clearly seen over the full range of concentrations tested (5 ng/ml down to 5 pg/ml) with no obvious dose response (Figure 6). Similar potent effects were seen in this type of rapid assay, which is run over 3 h in serum-free media, when murine MIF and *B. malayi* MIF-1 were tested, and which implicated the tautomerase activity in the mode of inhibition of cell migration [25]. Most other studies using assays of migration which operate over 16–24 h in serum- or serum albumin-containing media have noted high activity only at higher concentrations (20–200 ng/ml), which are more easily interpretable in relation to levels of MIF in plasma (1–50 ng/ml; D. J. Meyer, unpublished work).

When MIF (5 ng/ml) was added to the lower chamber, monocyte migration was increased by 69% ($P < 0.0005$) with TsMIF and by 42% ($P < 0.025$) with rHsMIF, thus dem-




Figure 6 Migration inhibition of human monocytes

Migration of human monocytes through 5 μ m pores in a polycarbonate filter was determined in serum-free medium over 3 h as described in the text. Monocytes and MIF solution or control solution lacking MIF were added to the upper chamber. HsMIF (■) and TsMIF (▲) significantly inhibited migration at all concentrations tested; *P* values ranged from 10^{-4} to 10^{-6} .

onstrating significant chemotactic activity as seen in a comparable assay with murine MIF or *B. malayi* MIF-1 [25].

T-lymphocyte activation

A number of T-cell-dependent immune parameters are depressed during trichinosis, and MIF, secreted by T-lymphocytes, has been shown to be essential for T-cell-receptor-stimulated proliferation [10]. Therefore, to test whether TsMIF might act as an immunosubversive factor, that is, an antagonist of mammalian MIF, it was incubated with murine splenocytes or with CD4⁺-positive T cells purified therefrom, stimulated with anti-CD3 monoclonal antibody, and subsequent proliferation measured. TsMIF in the range 5–500 ng/ml, added at the same time as the activation step, had no significant effect on T-cell proliferation, nor were the levels of IL-2, IL-4 or IFN- γ in the cell supernatants significantly altered.

TsMIF secretion

To estimate the amounts of TsMIF which might be secreted from larvae into the host, TsMIF larvae isolated from muscle tissue were incubated in tissue culture, either with or without activation by bile. TsMIF was assayed after concentration of the spent medium and compared with the total protein secreted. TsMIF was detected at 18 ng/mg of secreted protein in the medium in the absence of bile-salt activation, and at 55 ng/mg secreted protein after bile-salt treatment. The latter value was approx. 5% of the content of TsMIF isolated from the soluble fraction of whole larvae (1160 ng/mg of protein).

DISCUSSION

The cDNA sequences of TsMIF and TtMIF (Figure 1) are not particularly closely related according to percentage identity, but clearly share certain highly conserved residues as well as residues (discussed below) which differentiate them from mammalian MIFs, including Ala⁵⁶, Phe⁵⁹ (both usually cysteine), Asn⁴², His⁹⁷ and Val⁹⁹. Recently a phosphorylation of Ser⁸⁹ of HsMIF was observed [49], and this is another residue which is different (proline) in the nematode MIFs.

rTsMIF was not distinguishable by HPLC, SDS/PAGE or specific activity towards L-dopachrome methyl ester from the

native enzyme isolated from *T. spiralis* larvae, and the mass spectrum of rTsMIF gave the predicted value for an unmodified protein. Therefore it should be suitable for the analysis of structure and function of TsMIF.

Generally, evidence was obtained which showed that TsMIF has properties similar to those of human MIF. Thus TsMIF showed closely similar structure in solution and in the crystal to that of mammalian MIFs, and demonstrated a comparable tautomerase activity towards phenylpyruvate. Both TsMIF and HsMIF showed extremely potent inhibition of monocyte migration and chemotactic activity in serum-free medium, similar to that seen previously with *B. malayi* MIF-1 [25]. TsMIF also showed minor effects similar to those of HsMIF on bacterial-endotoxin-stimulated production of nitric oxide (as nitrite) by cultured macrophages (R. Kumari and D. J. Meyer, unpublished work). The absence of effects of TsMIF upon anti-CD3-stimulated T-cell mitogenesis indicated that it is not a subversive antagonist of host MIF action, although it remains to be seen whether it has immunoglobulin-glycosylation-inhibition factor activity [49] or natural killer-cell antagonism activity [8], which might be advantageous to the parasite. Furthermore, the discovery of a partial sequence of TtMIF (a pseudogene) adjacent to a sequence homologous to the Jab1 domain of human AMSH possibly implicates TtMIF, at least in signal-transduction pathways related to cell growth, as seen for mammalian MIF [16]. With or without activation by bile (which is necessary for the acquisition of infectivity), the levels of TsMIF detected in spent medium of cultured larvae are too low compared with the intracellular level to indicate that TsMIF is primarily a secretory product under these conditions. However, the secreted amount, compared with total secreted protein, is proportionately much higher with *T. spiralis* larvae (18–55 ng/mg of protein) than is MIF in normal human plasma (0.04–0.4 ng/mg of protein (D. J. Meyer, unpublished work) and might therefore be sufficient to affect monocyte migration locally in infected tissue.

Notable differences between TsMIF and mammalian MIFs were seen only in structural and enzymic studies. In the crystal structure, the obstruction in TsMIF of the continuous central channel of mammalian MIFs is due to hydrogen bonding between Asn⁴² (valine in mammalian MIFs) and the conserved Gln⁴⁵. This may also occur in TtMIF and the *Brugia* MIFs, which also have Asn⁴². The relatively low tautomerase activity of TsMIF towards *p*-hydroxyphenylpyruvate appears to be due mainly to an altered disposition of residues 97 (histidine) and 62 (methionine), which are related to the change of Tyr⁹⁹ to valine (Figure 5). Val⁹⁹ also occurs in TtMIF and the *Brugia* MIFs. Hence, although residue 97 is unique to TsMIF, the extension of the active-site pocket into the central channel (Figure 4) might also occur in these MIFs. The close conservation around the active site Pro¹ and Lys⁶² compared with the distal regions of the pocket suggest that there are different endogenous substrates for the tautomerase activity of TsMIF and mammalian MIFs. The unidentified electron density at the active site of crystalline TsMIF might have been acquired during crystallization; however, the partial occupation of subunits observed would suggest that the ligand was bound during growth in *E. coli*, and any fully liganded trimers failed to bind the phenyl-agarose matrix and hence were not purified. The co-induction of tryptophan indole lyase/ β -conjugate lyase also suggests that a pathway of tryptophan metabolism or GSH conjugation was affected by the presence of TsMIF, an observation also consistent with the presence of an endogenous ligand. Further differences between TsMIF and HsMIF include the former's lower sensitivity to inhibition of tautomerase activity by haematin [34], and its relatively high activity towards L-dopachrome methyl ester (Table

3), not seen in TtMIF. The reasons for these differences are not yet apparent. Perhaps most significant are the lack of cysteine residues. Cysteine residues at positions 56 and 59 in mammalian MIFs can participate in thiol ↔ disulphide exchange with hydroxyethyl disulphide or insulin [50], and Cys⁵⁹ has also been implicated in cytokine activity and the interaction with Jab1 [16]. Cysteine residues, particularly Cys⁵⁹, of mammalian MIFs are important also in the acquisition of the immunoinhibitory properties of glycosylation inhibition factor (inhibition of maturation of immunoglobulins) via mixed-disulphide formation or alkylation and a natural Cys⁵⁹ cysteinylated form corresponds to natural bioactive immunoglobulin glycosylation inhibition factor [49].

Taken together, the results indicate that TsMIF is partially orthologous to mammalian MIF, and it might prove useful in determining the mechanisms of action of human MIF, e.g. resolving the importance of cysteine–thiol–disulphide reactions and of the tautomerase activity. Further study will be required to determine whether TsMIF and TtMIF function in the host–parasite relationship, and whether they are potential therapeutic targets or even immunomodulatory therapeutics.

We are grateful to Quentin Bickle and Marco Albonico for collection of *T. trichiura* adults for TtMIF isolation; to Don Bundy and assistants for help in providing *T. trichiura* for RNA isolation, to Rachel Lawrence for the cytokine assay materials, and to Katherine Bodman-Smith and Sylvia Bino for help with monocyte and macrophage preparation. The project was supported by the Wellcome Trust (P049059) and the Biotechnology and Biological Sciences Research Council Bloomsbury Centre for Structural Biology.

REFERENCES

- Behnke, J. M., Barnard, C. J. and Wakelin, D. (1992) Understanding chronic nematode infections: evolutionary considerations, current hypotheses and the way forward. *Int. J. Parasitol.* **22**, 861–907
- Maizels, R. M., Bundy, D. A. P., Selkirk, M. E., Smith, D. F. and Anderson, R. M. (1993) Immunological modulation and evasion by helminth parasites in human populations. *Nature (London)* **365**, 797–805
- Barriga, O. O. (1978) Depression of cell-mediated immunity following inoculation of *Trichinella spiralis* extract in the mouse. *Immunology* **34**, 167–173
- Gerencser, M., Marinculic, A., Rapić, D., Franković, M. and Valpotic, I. (1992) Immunosuppression of *in vivo* and *in vitro* lymphocyte responses in swine induced by *Trichinella spiralis* or excretory–secretory antigens of the parasite. *Vet. Parasitol.* **44**, 263–273
- Pennock, J. L., Behnke, J. M., Bickle, Q. D., Devaney, E., Grecnis, R. K., Isaac, R. E., Joshua, G. W. P., Selkirk, M. E., Zhang, Y. and Meyer, D. J. (1998) Rapid purification and characterization of L-dopachrome methyl ester tautomerase (macrophage-migration-inhibitory factor) from *Trichinella spiralis*, *Trichuris muris* and *Brugia pahangi*. *Biochem. J.* **335**, 495–498
- Calandra, T., Bernhagen, J., Metz, C. N., Spiegel, L. A., Bacher, M., Donnelly, T., Cerami, A. and Bucala, R. (1995) MIF as a glucocorticoid-induced modulator of cytokine production. *Nature (London)* **377**, 68–71
- Tomura, T., Watarai, H., Honma, N., Sato, M., Iwamatsu, A., Kato, Y., Kuroki, R., Nakano, T., Mikayama, T. and Ishizaka, K. (1999) Immunosuppressive activities of recombinant glycosylation-inhibiting factor mutants. *J. Immunol.* **162**, 195–202
- Apte, R. S., Sinha, D., Mayhew, E., Wistow, G. J. and Niederkorn, J. Y. (1998) Role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. *J. Immunol.* **160**, 5693–5696
- Hudson, J. D., Shoaibi, M. A., Maestro, R., Carnero, A., Hannon, G. J. and Beach, D. H. (1999) A proinflammatory cytokine inhibits p53 tumour suppressor activity. *J. Exp. Med.* **190**, 1375–1382
- Bacher, M., Metz, C. N., Calandra, T., Mayer, K., Chesney, J., Lohoff, M., Gemsa, D., Donnelly, T. and Bucala, R. (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. *Proc. Natl. Acad. Sci. U.S.A.* **93**, 7849–7854
- Waeger, G., Calandra, T., Roduit, R., Haefliger, J.-A., Bonny, C., Thompson, N., Thorens, B., Temler, E., Meinhardt, A., Bacher, M., Metz, C. N., Nicod, P. and Bucala, R. (1997) Insulin secretion is regulated by the glucose-dependent production of islet β cell macrophage migration inhibitory factor. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 4782–4787
- Chesney, J., Metz, C., Bacher, M., Peng, T., Meinhardt, A. and Bucala, R. (1999) An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. *Mol. Med.* **5**, 181–191
- Mitchell, R. A., Metz, C. N., Peng, T. and Bucala, R. (1999) Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A₂ activation by macrophage migration inhibitory factor. *J. Biol. Chem.* **274**, 18100–18106
- Bozza, M., Satoskar, A. R., Lin, G., Lu, B., Humbles, A. A., Gerard, C. and David, J. R. (1999) Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. *J. Exp. Med.* **189**, 341–346
- Cunha, F. Q., Weiser, Y. W., David, J. R., Moss, D. W., Moncada, S. and Liew, F. Y. (1993) Recombinant migration inhibitory factor induces nitric oxide synthase in murine macrophages. *J. Immunol.* **150**, 1908–1912
- Kleeman, R., Hausser, A., Geiger, G., Mishcke, R., Burger-Kentscher, A., Flieger, O., Johannes, F.-J., Roger, T., Calandra, T., Kapurniotu, A. et al. (2000) Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. *Nature (London)* **408**, 211–216
- Esumi, N., Budarf, M., Ciccarelli, L., Sellinger, B., Kozak, C. A. and Wistow, G. (1998) Conserved gene structure and genomic linkage for D-dopachrome tautomerase (DDT) and MIF. *Mammal. Genome* **9**, 753–757
- Coggan, M., Whitbread, L., Whittington, A. and Board, P. (1998) Structure and organization of the human theta-class glutathione S-transferase and D-dopachrome tautomerase complex. *Biochem. J.* **334**, 617–623
- Sugimoto, H., Taniguchi, M., Nakagawa, A., Tanaka, I., Suzuki, M. and Nishihara, J. (1999) Crystal structure of human D-dopachrome tautomerase, a homologue of macrophage migration inhibitory factor, at 1.54 Å resolution. *Biochemistry* **38**, 3268–3279
- Sun, H.-W., Bernhagen, J., Bucala, R. and Lolis, E. (1996) Crystal structure at 2.6-Å resolution of human macrophage migration inhibitory factor. *Proc. Natl. Acad. Sci. U.S.A.* **93**, 5191–5196
- Kato, Y., Muto, T., Tomura, T., Watarai, H., Mikayama, T., Ishizaka, K. and Kuroki, R. (1996) The crystal structure of human glycosylation-inhibiting factor is a trimeric barrel with three 6-stranded β-sheets. *Proc. Natl. Acad. Sci. U.S.A.* **93**, 3007–3010
- Bendrat, K., Al-Abed, Y., Callaway, D. J. E., Peng, T., Calandra, T., Metz, C. N. and Bucala, R. (1997) Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. *Biochemistry* **36**, 15356–15362
- Lubetsky, J. B., Swope, M., Dealwis, C., Blake, P. and Lolis, E. (1999) Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity. *Biochemistry* **38**, 7346–7354
- Johnson, W. H., Czerwinski, R. M., Stamps, S. L. and Whitman, C. P. (1999) A kinetic and stereochemical investigation of lysine-32 in the phenylpyruvate tautomerase activity catalysed by macrophage migration inhibitory factor. *Biochemistry* **38**, 16024–16033
- Pastrana, D. V., Raghavan, N., Fitzgerald, P., Eisinger, S. W., Metz, C., Bucala, R., Schleimer, R. P., Bickel, C. and Scott, A. L. (1998) Filarial nematode parasites secrete a homologue of the human cytokine macrophage migration inhibitory factor. *Infect. Immun.* **66**, 5955–5963
- Arden, S. R., Smith, A. M., Booth, M. J., Tweedie, S., Gounaris, K. and Selkirk, M. E. (1997) Identification of serine/threonine protein kinases secreted by *Trichinella spiralis* infective larvae. *Mol. Biochem. Parasitol.* **90**, 111–119
- Totty, N. F., Waterfield, M. D. and Hsuan, J. J. (1992) Accelerated high-sensitivity microsequencing of proteins and peptides using a miniature reaction cartridge. *Protein Sci.* **1**, 1215–1224
- Su, X. Z., Prestwood, A. K. and McGraw, R. A. (1991) Cloning and expression of complementary DNA encoding an antigen of *Trichinella spiralis*. *Mol. Biochem. Parasitol.* **45**, 331–336
- Habeeb, A. F. S. A. (1972) Reaction of protein sulphhydryl groups with Ellman's reagent. *Methods Enzymol.* **25**, 457–469
- Ashton, D. S., Beddell, R. C., Green, B. N. and Oliver, R. W. A. (1994) Rapid validation of molecular structures of biological samples by electrospray-mass spectrometry. *FEBS Lett.* **342**, 1–6
- Wallace, B. A. and Teeters, C. L. (1987) Differential absorption flattening optical effects are significant in the circular dichroism spectra of large membrane fragments. *Biochemistry* **26**, 65–70
- Hennessey, Jr J. P. and Johnson, Jr W. C. (1982) Experimental errors and their effect on analyzing circular dichroism spectra of proteins. *Anal. Biochem.* **125**, 177–188
- Brahms, S. and Brahms, J. (1980) Determination of protein secondary structure in solution by vacuum ultraviolet circular dichroism. *J. Mol. Biol.* **138**, 149–178
- Pennock, J. L., Wipasa, J., Gordge, M. P. and Meyer, D. J. (1998) Interaction of macrophage-migration-inhibitory factor with haematin. *Biochem. J.* **331**, 905–908
- Taylor, A. B., Johnson, Jr W. H., Czerwinski, R. M., Li, H.-S., Hackert, M. L. and Whitman, C. P. (1999) Crystal structure of macrophage migration inhibitory factor complexed with (E)-2-fluoro-p-hydroxycinnamic acid at 1.8 Å resolution: implications for enzymatic catalysis and inhibition. *Biochemistry* **38**, 7444–7452
- Jancarik, K. and Kim, S.-H. (1991) Sparse matrix sampling: a screening method for crystallisation of proteins (1991). *J. Appl. Crystallogr.* **24**, 409–411

- 37 Matthews, B. W. (1969) Solvent content of protein crystals. *J. Mol. Biol.* **33**, 491–497
- 38 Collaborative Computational Project Number 4 (1994) The CCP4 suite: programs for protein crystallography. *Acta Crystallogr.* **D50**, 760–763
- 39 Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J.-S., Kuszewski, J., Nilges, M., Pannu, N. S. et al. (1998) Crystallography and NMR System: A new software suite for macromolecular structure determination. *Acta Crystallogr.* **D54**, 905–921
- 40 Jones, T. A., Zou, J. Y., Cowan, S. W. and Kjeldgaard, M. (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. *Acta Crystallogr.* **A47**, 110–119
- 41 Mak, C. H. and Ko, R. C. (1999) Characterization of endonuclease activity from excretory/secretory products of a parasitic nematode, *Trichinella spiralis*. *Eur. J. Biochem.* **260**, 477–481
- 42 Tanaka, N., Kaneko, K., Asao, H., Kasai, H., Endo, Y., Fujita, T., Takeshita, T. and Sugamura, K. (1999) Possible involvement of a novel STAM-associated molecule 'AMSH' in intracellular signal transduction mediated by cytokines. *J. Biol. Chem.* **274**, 19129–19135
- 43 Mischke, R., Gessner, A., Kapurniotu, A., Juttner, S., Kleemann, R., Brunner, H. and Bernhagen, J. (1997) Structure activity studies of the cytokine macrophage migration inhibitory factor (MIF) reveal a critical role for its carboxy terminus. *FEBS Lett.* **414**, 226–232
- 44 Yang, J. T., Wu, C. S. and Martinez, H. M. (1986) Calculation of protein conformation from circular dichroism. *Methods Enzymol.* **130**, 208–269
- 45 Sun, H. W., Swope, M., Cinquina, C., Bedarkar, S., Bernhagen, J., Bucala, R. and Lolis, E. (1996) The subunit structure of human macrophage migration inhibitory factor: evidence for a trimer. *Protein Eng.* **9**, 631–635
- 46 Kabsch, W. and Sander, C. (1983) Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. *Biopolymers* **12**, 2577–2637
- 47 Esnouf, R. M. (1999) Further additions to MolScript version 1.4, including reading and contouring of electron density maps. (1999). *Acta Crystallogr.* **D55**, 938–940
- 48 Nicholls, A., Sharp, K. A. and Honig, B. (1991) Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. *Proteins* **11**, 281–296
- 49 Watarai, H., Nozawa, R., Tokunaga, A., Yuyama, N., Tomas, M., Hinohara, A., Ishizaki, K. and Ishii, Y. (2000) Posttranslational modification of the glycosylation inhibiting factor (GIF) gene product generates bioactive GIF. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 13251–13256
- 50 Kleeman, R., Kapurniotu, A., Frank, R. W., Gessner, A., Mischke, R., Flieger, O., Juttner, S., Brunner, H. and Bernhagen, J. (1998) Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. *J. Mol. Biol.* **280**, 85–102

Received 12 January 2001/12 March 2001; accepted 26 April 2001